XML 15 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 28, 2026
Mar. 29, 2025
Revenues:    
Total revenues $ 10,551,370 $ 10,538,492
Expenses:    
Cost of product revenues 5,609,253 7,629,467
Research and development – Funded 3,806,233 638,719
Research and development – Internal 1,105,336 1,477,202
Selling, general and administrative 6,017,411 4,701,061
Total operating expenses 16,538,233 14,446,449
Loss from operations (5,986,863) (3,907,957)
Non-operating income (expense), net:    
Interest income 94,162 446,448
Other (expense) income, net (224,613) 324,934
Foreign currency transaction gains 114,335 99,163
Loss on impairment of investments, net (24,121)
Gain on investments 2,307,961
Total non-operating income 2,291,845 846,424
Loss before provision for income taxes (3,695,018) (3,061,533)
Provision for income taxes (57,020) (52,000)
Net loss (3,752,038) (3,113,533)
Dividends and deemed dividends on Series A convertible preferred stock (35,000)
Net loss attributable to common stockholders $ (3,787,038) $ (3,113,533)
Net loss per share attributable to common stockholders:    
Basic $ (0.02) $ (0.02)
Diluted $ (0.02) $ (0.02)
Weighted average number of common shares outstanding:    
Basic 186,903,857 166,118,010
Diluted 186,903,857 166,118,010
Net Product Revenues [Member]    
Revenues:    
Total revenues $ 5,424,720 $ 9,229,885
Research and Development Revenues [Member]    
Revenues:    
Total revenues 1,290,416 1,236,667
Grant Income [Member]    
Revenues:    
Total revenues 3,441,695
Collaboration Arrangement Income [Member]    
Revenues:    
Total revenues 329,611
License and Other Revenues [Member]    
Revenues:    
Total revenues $ 64,928 $ 71,940